* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download S073510970802826X_mmc1
Survey
Document related concepts
Coronary artery disease wikipedia , lookup
Electrocardiography wikipedia , lookup
Remote ischemic conditioning wikipedia , lookup
Heart failure wikipedia , lookup
Antihypertensive drug wikipedia , lookup
Cardiac surgery wikipedia , lookup
Mitral insufficiency wikipedia , lookup
Cardiac contractility modulation wikipedia , lookup
Jatene procedure wikipedia , lookup
Hypertrophic cardiomyopathy wikipedia , lookup
Myocardial infarction wikipedia , lookup
Ventricular fibrillation wikipedia , lookup
Management of acute coronary syndrome wikipedia , lookup
Dextro-Transposition of the great arteries wikipedia , lookup
Arrhythmogenic right ventricular dysplasia wikipedia , lookup
Transcript
Online Appendix for the following November 4 JACC article TITLE: A Randomized Clinical Trial to Evaluate the Safety and Efficacy of a Percutaneous Left Ventricular Assist Device (Impella LP2.5) Versus Intra-Aortic Balloon Pumping For Treatment of Cardiogenic Shock Caused by Myocardial Infarction AUTHORS: Melchior Seyfarth, MD, Dirk Sibbing, MD, Iris Bauer, MS, Georg Fröhlich, MD, Lorenz Bott-Flügel MD, Robert Byrne MB, MRCPI, Josef Dirschinger, MD, Adnan Kastrati, MD, Albert Schömig, MD APPENDIX Patient Population Eligible participants for this study were patients with: 1) acute myocardial infarction (AMI) <48 h, confirmed by ischemic symptoms for at least 30 min with elevated cardiac markers or ST-segment elevation or left bundle branch block. An AMI was suspected when patients were resuscitated and cardiac markers and/or electrocardiographic changes met criteria for AMI/acute coronary syndrome; 2) Cardiogenic shock was defined using both clinical and hemodynamic criteria as previously described in the SHOCK trial (1). In brief, clinical criteria were hypotension (systolic blood pressure <90 mm Hg) and a heart rate >90 beats/min or the need for positive inotropic drugs to maintain a systolic blood pressure >90 mm Hg and end-organ hypoperfusion (cool extremities or a urine output of <30 ml/h) or pulmonary edema. Hemodynamic criteria were either a cardiac index of no more than 2.2 l/min per square meter of body surface area and a pulmonary capillary wedge pressure >15 mm Hg or an angiographically measured left ventricular ejection fraction <30% and left ventricular end diastolic pressure >20 mm Hg. The onset of shock had to be within 24 h. Exclusion criteria were specified as: age <18 years; prolonged resuscitation (>30 1 min); hypertrophic obstructive cardiomyopathy; definite thrombus in left ventricle; treatment with intra-aortic balloon pump; severe valvular disease or mechanical heart valve; cardiogenic shock caused by mechanical complications of AMI such as ventricular septal defect, acute mitral regurgitation greater than second degree, or rupture of the ventricle; predominant right ventricular failure or the need for a right ventricular assist device; sepsis; known cerebral disease; bleeding with a need for surgical intervention; pulmonary embolism; allergy to heparin or any known coagulopathy; aortic regurgitation greater than second degree; pregnancy; or inclusion in another study or trial. The study was performed in Germany between September 2004 and January 2007. Statistical Analysis The primary end point of the study was the hemodynamic improvement within 30 min after implantation defined as the increase in cardiac index from baseline. We applied a modified intention-to-treat principle because 1 patient could not be included in the analysis because of unavailability of the assigned device after enrollment. For patients not surviving to the time point for primary end point calculation, we performed 2 kinds of analysis by first assuming a null effect of the device and second assuming an effect equal to the worst hemodynamic effect in the group. Because only 1 patient died before implantation (Impella group), we were able to analyze the primary end point by including this patient in different ways, none of which affected the statistical differences in the data. Secondary end points of the study were hemodynamic and metabolic parameters every second hour during the first 6 h and every eighth hour as long as the device was implanted; all-cause mortality at 30 days; devicerelated complications including hemolysis, major bleeding, cerebrovascular events, and limb ischemia; and multiple-organ dysfunction scores at 30 days using Multiple Organ 2 Dysfunction Score and Sepsis-related Organ Failure Assessment criteria (2,3). With a sample size of 26 patients, we achieved 80% power to detect a significant enhancement of cardiac index from +0.15 l/min in patients with intra-aortic balloon pump to +0.50 l/min in patients with Impella LP2.5 at an α level of 0.05. Hemodynamic parameters (arterial pressure, pulmonary arterial pressure, right atrial pressure, pulmonary capillary wedge pressure, cardiac index, cardiac output, heart rate, systemic vascular resistance) were analyzed as mean ± SD. Additionally, cardiac power index (CPI) was calculated as CI × mean arterial pressure × 0.0022 (4). For patients with augmentation of the Impella LP2.5 device, endogenous CPI of the left ventricle was calculated as CPILV = CPItotal − CPIImpella. The CPIImpella value was based on the actual pump flow of the device. Patient data are presented as mean ± SD, continuous variables as median and interquartile range, and categorical variables as counts and proportions (%). Data were presented as median and interquartile range when parametric assumptions were inappropriate (e.g., serum levels of free hemoglobin). Differences between the groups were tested with the use of 2-tailed t test for parametric variables and Mann-Whitney U tests for continuous data, χ2 test or Fisher exact test for categorical data as appropriate, and were considered as being statistically significant at a 2-sided value of p < 0.05. Analysis of survival (Kaplan-Meier method) was performed using the Log-rank test. All statistical analyses were performed with SPSS software (SPSS Inc., Chicago, Illinois). References 1. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999;341:625–34. 3 2. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995;23:1638–52. 3. Vincent JL, Moreno R, Takala J, et al., on behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22:707–10. 4. Cotter G, Moshkovitz Y, Kaluski E, et al. The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. Eur J Heart Fail 2003;5:443–51. 4